98%
921
2 minutes
20
The evaluation of autonomic nervous system (ANS) function and coronary physiology through quantitative flow ratio (QFR) analysis provides a precise method for assessing the severity and prognosis of acute coronary syndrome (ACS). This study aimed to develop and validate a risk score model for predicting the long-term prognosis of non-ST-elevation ACS (NSTE-ACS) patients who underwent complete and successful percutaneous coronary intervention (PCI). NSTE-ACS patients who underwent complete and successful PCI with preoperative and postoperative QFR measurements between January 2018 and December 2020 in our medical center were included. 24-hour Holter monitoring was performed to assess deceleration capacity (DC) and heart rate variability (HRV) parameters. The primary endpoint was the occurrence of major adverse cardiac events (MACEs). The training cohort consisted of 271 patients, while the testing cohort consisted of 119 patients. The nomogram considered diabetes, normalized low-frequency (nLF) power/normalized high-frequency (nHF) power, DC, cardiac troponin I (cTnI), post-PCI QFR of the target vessel. The model demonstrated excellent discriminative ability, with area under the curve (AUC) values of 0.874 (95% CI: 0.809-0.939) for 1-year MACE prediction in the training cohort and 0.893 (95% CI: 0.808-0.978) in the testing cohort. For 2-year MACE prediction, the AUC values were 0.882 (95% CI: 0.822-0.942) and 0.842 (95% CI: 0.724-0.960) in the training and testing cohorts. We successfully developed and validated a risk stratification system that integrates baseline clinical characteristics (diabetes, cTnI levels), ANS parameters (nLF/nHF ratio, DC), and coronary physiological assessment (post-PCI QFR). This model effectively predicts MACEs in NSTE-ACS patients following PCI, providing valuable prognostic information for clinical decision-making.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080570 | PMC |
http://dx.doi.org/10.7150/ijms.111214 | DOI Listing |
Background: In the presence of a potent P2Yinhibitor such as prasugrel, the additional clinical antithrombotic benefit of aspirin is unclear. The feasibility of prasugrel monotherapy without aspirin after percutaneous coronary intervention (PCI) has been demonstrated in chronic coronary syndrome, but is yet to be assessed in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) and low anatomical complexity.
Methods And Results: ASET-Japan is a single-arm study investigating the safety of prasugrel 12-month monotherapy with a locally approved dose (loading 20 mg; maintenance 3.
Medicina (Kaunas)
August 2025
Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.
: Older patients with ACS are less frequently treated with an invasive strategy, which may negatively impact their survival. This study aimed to investigate treatment approaches in elderly ACS patients and compare outcomes between invasively and conservatively treated groups. : This retrospective study included consecutive patients aged 80 or older who presented with ACS at two tertiary institutions from November 2018 to October 2023.
View Article and Find Full Text PDFLife (Basel)
August 2025
Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania.
Non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) often coexists with multivessel coronary artery disease (MVD), complicating treatment decisions. Current guidelines suggest complete revascularization (CR), yet robust evidence in hemodynamically stable patients remains insufficient. However, the comparative benefit of CR over incomplete revascularization (IR) in reducing ischemic events and improving cardiac function in this population is not well established.
View Article and Find Full Text PDFJACC Adv
August 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address:
Background: Post-percutaneous coronary intervention (PCI) angina affects 20% to 40% of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) survivors but remains a clinical challenge due to its unpredictable course.
Objectives: This study aimed to validate a rapid 90-second optically pumped magnetometer magnetocardiography (OPM-MCG) test for diagnosing post-PCI angina and develop a predictive model using dynamic MCG parameters.
Methods: NSTE-ACS patients who underwent pre- and post-PCI OPM-MCG scans were included.
Eur Heart J
August 2025
Department of Clinical and Molecular Medicine, Sapienza University of Rome, Via di Grottarossa 1035, 00198, Rome Italy.
Background And Aims: Several randomized controlled trials (RCTs) have compared fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with angiography-guided PCI in different clinical settings, yielding mixed results. This individual patient data meta-analysis focused on trials where FFR was used to assess intermediate coronary lesions in chronic coronary syndrome (CCS) or non-culprit vessels in non-ST-elevation acute coronary syndromes (NSTE-ACS).
Methods: Randomized controlled trials comparing FFR- vs angiography-guided PCI with a minimum follow-up of 1 year were searched.